EP2608776A2 - Préparations de cefpodoxime proxétil - Google Patents

Préparations de cefpodoxime proxétil

Info

Publication number
EP2608776A2
EP2608776A2 EP11782258.5A EP11782258A EP2608776A2 EP 2608776 A2 EP2608776 A2 EP 2608776A2 EP 11782258 A EP11782258 A EP 11782258A EP 2608776 A2 EP2608776 A2 EP 2608776A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
composition according
range
agent
cefpodoxime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11782258.5A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bilgic Mahmut
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2608776A2 publication Critical patent/EP2608776A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • Water dispersible tablets of the present invention can be prepared as specified below, yet the invention is not restricted to these examples.
  • EXAMPLE 1 Formulation and process for preparation of water dispersible granule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

L'invention concerne des préparations pharmaceutiques comprenant du cefpodoxime proxétil.
EP11782258.5A 2010-08-25 2011-08-24 Préparations de cefpodoxime proxétil Withdrawn EP2608776A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07106A TR201007106A1 (tr) 2010-08-25 2010-08-25 Sefpodoksim proksetil formülasyonları.
PCT/TR2011/000200 WO2012026907A2 (fr) 2010-08-25 2011-08-24 Préparations de cefpodoxime proxétil

Publications (1)

Publication Number Publication Date
EP2608776A2 true EP2608776A2 (fr) 2013-07-03

Family

ID=44947169

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11782258.5A Withdrawn EP2608776A2 (fr) 2010-08-25 2011-08-24 Préparations de cefpodoxime proxétil

Country Status (3)

Country Link
EP (1) EP2608776A2 (fr)
TR (1) TR201007106A1 (fr)
WO (1) WO2012026907A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142506B (zh) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 一种头孢泊肟酯颗粒剂及其制备方法
CN103230367B (zh) * 2013-05-07 2014-11-12 山东罗欣药业集团股份有限公司 一种头孢泊肟酯组合物干混悬剂及其制备方法
CN107693491B (zh) * 2017-04-20 2020-06-30 广东金城金素制药有限公司 一种小儿用药物组合物及制剂
CN108815130A (zh) * 2018-08-27 2018-11-16 邓倩 一种头孢泊肟酯药片及其生产工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
BR0207640A (pt) * 2001-02-27 2004-07-27 Ranbaxy Lab Ltd Composição farmacêutica oral de cefpodoxima proxetil
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
AU2003249116A1 (en) * 2002-07-16 2004-02-02 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
JP2008540403A (ja) * 2005-05-05 2008-11-20 ルピン・リミテッド セファロスポリンの安定化経口用医薬組成物
TR201002878A2 (tr) * 2010-04-13 2011-10-21 Bi̇lgi̇ç Mahmut Sefpodoksim proksetil içeren farmasötik bileşimler.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012026907A2 *

Also Published As

Publication number Publication date
WO2012026907A2 (fr) 2012-03-01
TR201007106A1 (tr) 2012-03-21
WO2012026907A3 (fr) 2012-09-13

Similar Documents

Publication Publication Date Title
EP2528589B1 (fr) Formulations effervescentes stables contenant du céfaclor
US20140079647A1 (en) Cefdinir and cefixime formulations and uses thereof
WO2012060788A1 (fr) Formulations de céphalosporines avec teneur en humidité contrôlée
EP2568959A2 (fr) Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération
EP2608776A2 (fr) Préparations de cefpodoxime proxétil
WO2012060790A2 (fr) Formulations de cefpodoxime proxétil dispersibles dans l'eau
WO2011142730A1 (fr) Composition pharmaceutique comprenant la céfixime et un composé dérivé de l'acide clavulanique
EP2515860B1 (fr) Compositions pharmaceutiques améliorées comprenant cefdinir
WO2011129792A1 (fr) Formulations dispersibles dans l'eau comprenant le cefpodoxime proxétil
WO2011139249A2 (fr) Composition pharmaceutique renfermant du cefdinir
US20130129791A1 (en) Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
EP2566449B1 (fr) Compositions pharmaceutiques comprenant du ceftibutène
WO2011093828A2 (fr) Formes posologiques solides comprenant du cefprozil
EP2566451B1 (fr) Composition pharmaceutique contentant de cefditoren pivoxil
WO2012060787A1 (fr) Comprimés contenant du cefdinir
WO2011078830A1 (fr) Formulation effervescente à dispersion rapide
WO2011093821A1 (fr) Formulations effervescentes comprenant du cefdinir et de l'acide clavulanique
WO2012060791A2 (fr) Procédé de production de compositions pharmaceutiques comprenant du cefdinir
WO2012026908A2 (fr) Préparations de cefpodoxime proxétil comprenant un agent régulateur de goût
EP2566450A2 (fr) Compositions pharmaceutiques comprenant du céfétamet
WO2012060792A1 (fr) Compositions pharmaceutiques comprenant au minimum 6% en poids de délitants
EP2575812A2 (fr) Composition pharmaceutique comprenant de l'acide clavulanique et du cefpodoxime proxetil
WO2012060793A2 (fr) Procédé de préparation de formulations de cefdinir
WO2012078121A2 (fr) Forme posologique orale solide comprenant cefdinir
EP2833872A1 (fr) Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130325

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BILGIC, MAHMUT

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BILGIC, MAHMUT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BILGIC, MAHMUT

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BILGIC, MAHMUT

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140310

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140301